Systematic review highlights SGLT2 inhibitors improve quality of life and patient-reported outcomes in type 2 diabetes, suggesting earlier treatment benefits.
Randomised evidence suggests SGLT2 inhibitors enhance EQ-5D Index score, diabetes-specific QoL and several PROs in T2DM, particularly in physical, emotional and treatment satisfaction domains, supporting their earlier use in this population.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: